My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Filatex India corrects on profit booking
Mar 09,2017

Meanwhile, the S&P BSE Sensex was down 8.96 points, 0.03% to Rs 28,892.98.

On the BSE, 1.99 lakh shares were traded on the counter so far as against the average daily volumes of 46,838 shares in the past one quarter. The stock had hit a high of Rs 107.80 so far during the day, which is also 52-week high for the counter. The stock hit a low of Rs 101 so far during the day. The stock had hit a 52-week low of Rs 34.55 on 9 March 2016.

The small-cap company has equity capital of Rs 43.50 crore. Face value per share is Rs 10.

Shares of Filatex India had rallied 56.58% in the preceding three trading sessions to settle at Rs 105.85 yesterday, 8 March 2017, from its closing of Rs 67.60 on 3 March 2017.

Filatex Indias net profit rose 25.4% to Rs 7.20 crore on 22.7% increase in net sales to Rs 366.59 crore in Q3 December 2016 over Q3 December 2015.

Filatex India is engaged in manufacture and trading of synthetic yarn and textiles. It manufactures polyester and polypropylene multifilament yarn, and polyester chips.

Powered by Capital Market - Live News

Lupin gains after launching pain relief drug in US
Mar 09,2017

The announcement was made during market hours today, 9 March 2017.

Meanwhile, the S&P BSE Sensex was down 7.21 points, 0.02% to Rs 28,894.73.

On the BSE, 13,000 shares were traded on the counter so far as against the average daily volumes of 70,904 shares in the past one quarter. The stock had hit a high of Rs 1,458.20 so far and a low of Rs 1,439.65 so far during the day.

The stock had hit a 52-week high 1,874.30 on 14 March 2016 and a 52-week low of Rs 1,294.05 on 29 March 2016.

The large-cap company has equity capital of Rs 90.31 crore. Face value per share is Rs 2.

Pharma major Lupin announced today, 9 March 2017, the launch of Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg after having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupins Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg are the AA rated generic equivalent of Mikart, Incs Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg. It is indicated for the relief of moderate to moderately severe pain.

Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg had combined US sales of $79.6 million (IMS MAT December 2016).

Lupins consolidated net profit rose 20.7% to Rs 633.11 crore on 31.5% increase in net sales to Rs 4404.94 crore in Q3 December 2016 over Q3 December 2015.

Lupin is a pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership position in the anti-TB segment.

Powered by Capital Market - Live News

Shree Renuka Sugars sweetens as board approves allotment to SCB
Mar 09,2017

The announcement was made after market hours yesterday, 8 March 2017.

Meanwhile, the S&P BSE Sensex was up 0.19 points or at 28,902.13

On the BSE, 8.19 lakh shares were traded on the counter so far as against the average daily volumes of 7.12 lakh shares in the past one quarter. The stock had hit a high of Rs 15.95 and a low of Rs 15.40 so far during the day. The stock had hit a 52-week high of Rs 19.18 on 15 June 2016 and a 52-week low of Rs 11.47 on 23 December 2016.

The small-cap company has equity capital of Rs 92.88 crore. Face value per share is Rs 1.

Shree Renuka Sugars said that as per the rectification package approved by the Joint Lenders Forum (JLF) under the Corrective Action Plan, the allotment committee of the board of directors of the company has approved the allotment of 1.64 crore equity shares at Rs 16.56 per share to Standard Chartered Bank (SCB), one of the JLF Lenders in lieu of and against the conversion of a part of the loans availed by the company from SCB.

Shree Renuka Sugars reported a net loss of Rs 42 crore in Q3 December 2016, higher than net loss of Rs 24.10 crore in Q3 December 2015. Net sales rose 33.4% to Rs 2041.40 crore in Q3 December 2016 over Q3 December 2015.

Shree Renuka Sugars is one of the leading sugar manufacturers in India.

Powered by Capital Market - Live News

Tamil Nadu Newsprint drops after announcing production stoppage
Mar 09,2017

The announcement was made after market hours yesterday, 8 March 2017.

Meanwhile, the S&P BSE Sensex, was currently down 6.39 points or 0.02% at 28,895.55

On BSE, so far 28,000 shares were traded in the counter, compared with an average daily volume of 14,892 shares in the past one quarter. The stock hit a high of Rs 340 and low of Rs 327 so far during the trading session. The stock had hit record high of Rs 392.45 on 13 October 2017. The stock hit 52-week low of Rs 198.55 on 16 March 2016.

The small-cap company has equity capital of Rs 69.21 crore. Face value per share is Rs 10.

Tamil Nadu Newsprint & Papers said that due to water shortage, the company has stopped production in Paper Machine II (PM II), in Unit I at Karur, Tamil Nadu from afternoon of 7 March 2017. The other two paper machines are in operation. The production in PM II will be resumed on availability of water.

Tamil Nadu Newsprint & Papers after net profit rose 39.18% to Rs 61.06 crore on 49.29% growth in net sales to Rs 698.85 crore in Q3 December 2016 over Q3 December 2015.

Tamil Nadu Newsprint & Papers (TNPL) manufactures newsprint and printing & writing paper using bagasse, a sugarcane residue, as primary raw material.

Powered by Capital Market - Live News

Kotak Bank slips as Uday Kotak pares stake
Mar 09,2017

Meanwhile, the S&P BSE Sensex was down 41.29 points or 0.14% at 28,860.65

On the BSE, 50,15 shares were traded on the counter so far as against the average daily volumes of 6.63 lakh shares in the past one quarter. The stock hit a high of Rs 825.50 and a low of Rs 820.55 so far during the day. The stock had hit a record high of Rs 839.75 yesterday, 8 March 2017. The stock had hit a 52-week low of Rs 631.50 on 15 March 2016.

The large-cap bank has equity capital of Rs 919.93 crore. Face value per share is Rs 5.

Shares of Kotak Mahindra Bank gained 0.88% to settle at Rs 824.50 yesterday, 8 March 2017 after the bank said its board of directors has approved increase in ceiling limit for investment by foreign investors in the equity share capital of the bank to 42% from 40% earlier. The announcement was made during market hours yesterday, 8 March 2017.

Kotak Mahindra Banks net profit rose 38.6% to Rs 879.76 crore on 11.02% growth in total income to Rs 5377.83 crore in Q3 December 2016 over Q3 December 2015.

Kotak Mahindra Bank is one of the leading private sector banks in India.

Powered by Capital Market - Live News

Satin Creditcare gains as board to consider issue of shares
Mar 08,2017

The announcement was made after market hours yesterday, 7 March 2017.

Meanwhile, the S&P BSE Sensex was down 96.77 points or 0.33% at 28,902.79

On BSE, so far 23,000 shares were traded in the counter as against average daily volume of 24,856 shares in the past one quarter. The stock hit a high of Rs 396.80 and a low of Rs 384.40 so far during the day.

The stock had hit a record high of Rs 716.70 on 28 July 2016. The stock had hit a 52-week low of Rs 289.90 on 29 March 2016. The stock had underperformed the market over the past one month till 7 March 2017, sliding 14.34% compared with the Sensexs 1.97% rise. The scrip had also underperformed the market over the past one quarter, falling 0.47% as against the Sensexs 10.53% rise.

The small-cap company has equity capital of Rs 37.57 crore. Face value per share is Rs 10.

Satin Creditcare Networks net profit rose 9.53% to Rs 16.44 crore on 44.83% growth in total income to Rs 208.35 crore in Q3 December 2016 over Q3 December 2015.

Satin Creditcare Network is one of the leading microfinance companies in India.

Powered by Capital Market - Live News

GAIL (India) drops after hitting almost 2-1/2 year high
Mar 08,2017

Meanwhile, the S&P BSE Sensex was down 90.16 points, or 0.31% to 28,909.40.

Huge volumes were traded on the counter. On the BSE, 19.14 lakh shares were traded in the counter so far, compared with average daily volumes of 2.63 lakh shares in the past one quarter. The stock had hit a high of Rs 534.40 in intraday trade, its highest level since 3 November 2014. The stock had hit a low of Rs 483.90 so far during the day. The stock hit a 52-week low of Rs 332.50 on 16 March 2016.

The stock had outperformed the market over the past one month till 7 March 2017, rising 9.97% compared with 2.34% gains in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 22.55% as against Sensexs 10.53% gains.

The large-cap company has equity capital of Rs 1268.48 crore. Face value per share is Rs 10.

GAIL (India)s shareholders on 6 March 2017 passed a resolution for issuance of bonus shares. On 22 February 2017, GAIL (India) had fixed 11 March 2017, as record date for 1:3 bonus issue. On 25 January 2017, GAIL (India)s board had approved issue of one bonus share for every three shares held.

GAIL (India)s net profit rose 45.4% to Rs 982.92 crore on 9.4% decline in net sales to Rs 12107.89 crore in Q3 December 2016 over Q3 December 2015.

GAIL (India), Indias largest natural gas company, is one of the seven Maharatna Public Sector Undertakings (PSUs). Government of India held 56.11% stake in the firm as per the shareholding pattern as on 31 December 2016.

Powered by Capital Market - Live News

Adani Power drops on profit booking
Mar 08,2017

Meanwhile, the S&P BSE Sensex was down 104.03 points, or 0.36% to 28,895.3

On the BSE, 11.07 lakh shares were traded on the counter so far as against the average daily volumes of 11.97 lakh shares in the past one quarter. The stock hit a high of Rs 40.70 and a low of Rs 38.20 so far during the day.

The stock had hit a 52-week high of Rs 41.30 yesterday, 7 March 2017. The stock had hit a 52-week low of Rs 23.35 on 9 November 2016. The stock had outperformed the market over the past one month till 7 March 2017, advancing 8.46% compared with the Sensexs 1.97% rise. The scrip had also outperformed the market over the past one quarter, gaining 27.04% as against the Sensexs 10.53% rise.

The large-cap company has equity capital of Rs 3732.86 crore. Face value per share is Rs 10.

Adani Power reported consolidated net loss of Rs 323.61 crore in Q3 December 2016, compared with the net profit of Rs 109.49 crore in Q3 December 2015. Net sales declined 6.15% to Rs 5803.52 crore in Q3 December 2016 over Q3 December 2015.

Adani Power is the largest private thermal power producer in India with an installed capacity of 10,480 MW.

Powered by Capital Market - Live News

Unichem Lab advances after receiving ANDA approval from USFDA for drug
Mar 08,2017

The announcement was made during market hours today, 8 March 2017.

Meanwhile, the S&P BSE Sensex was down 117.28 points or 0.4% at 28,883.09.

More than usual volumes were witnessed on the counter. On the BSE, 14,672 shares were traded on the counter so far as against the average daily volumes of 9,367 shares in the past one quarter. The stock had hit a high of Rs 268 and a low of Rs 260.80 so far during the day. The stock had hit a 52-week high of Rs 319.90 on 20 October 2016 and a 52-week low of Rs 210.10 on 18 March 2016.

The stock had underperformed the market over the past one month till 7 March 2017, falling 4.9% compared with 2.34% gains in the Sensex. The scrip had also underperformed the market in past one quarter, gaining 0.17% as against Sensexs 10.53% gains.

The small-cap company has equity capital of Rs 18.18 crore. Face value per share is Rs 2.

Unichem Laboratories announced that it has received abbreviated new drug application (ANDA) approval from the United States Food and Drug Administration (USFDA) for Rizatriptan Benzoate ODT 5mg & 10mg and Rizatriptan Benzoate Tablets USP, 5mg & 10mg which are therapeutically equivalent to Maxalt - MLT Tablets 5mg & 10mg and Maxalt Tablets 5mg 10mg of Merck & Company, Inc.

Rizatriptan Benzoate Tablets USP, 5mg & 10mg and Rizatriptan Benzoate ODT USP, 5mg & 10mg; is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine in adults and in pediatric patients 6 to 17 years of age.

The product will be commercialized from Unichems Goa plant. Active pharmaceutical ingredient (API) will also be made in house at Roha API plant.

Unichem Laboratories net profit rose 26.3% to Rs 26.11 crore on 15.1% rise in net sales to Rs 348.79 crore in Q3 December 2016 over Q3 December 2015.

Unichem Laboratories is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex APIs as well as dosage forms.

Powered by Capital Market - Live News

Cadila Healthcare gains after receiving final approval from USFDA for drug
Mar 08,2017

The announcement was made during market hours today, 8 March 2017.

Meanwhile, the S&P BSE Sensex was down 70.26 points or 0.24% at 28,929.30.

On the BSE, 55,640 shares were traded on the counter so far as against the average daily volumes of 1.19 lakh shares in the past one quarter. The stock had hit a high of Rs 444 and a low of Rs 436 so far during the day. The stock had hit a record high of Rs 460 on 17 February 2017. The stock had hit a 52-week low of Rs 305 on 12 April 2016.

The stock had outperformed the market over the past one month till 7 March 2017, rising 18.61% compared with 2.34% gains in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 11.35% as against Sensexs 10.53% gains.

The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.

Cadila Healthcare has received final approval from the United States Food & Drug Administration (USFDA) to market Tizanidine Hydrochloride Capsules, USP in strengths of 2 mg, 4 mg and 6 mg.

The drug, which is a muscle relaxant, will be produced at the special economic zone (SEZ) facility located at Ahmedabad. The estimated annual sales for Tizanidine Hydrochloride Capsules is $58.60 million as per IMS Jan 2017.

Cadila Healthcares consolidated net profit fell 34.6% to Rs 281.60 crore on 0.8% decrease in net sales to Rs 2249.60 crore in Q3 December 2016 over Q3 December 2015.

Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News

Adani Power leads losers in A group
Mar 08,2017

Adani Power lost 4.46% to Rs 38.60 at 13:36 IST. The stock topped the losers in the BSEs A group. On the BSE, 9.81 lakh shares were traded on the counter so far as against the average daily volumes of 12.27 lakh shares in the past two weeks.

NMDC dropped 4.21% to Rs 141.10. The stock was the second biggest loser in A group. On the BSE, 3.97 lakh shares were traded on the counter so far as against the average daily volumes of 3.86 lakh shares in the past two weeks.

Religare Enterprises fell 4.02% at Rs 216.15. The stock was the third biggest loser in A group. On the BSE, 9,898 shares were traded on the counter so far as against the average daily volumes of 3,225 shares in the past two weeks.

Cairn India declined 3.38% at Rs 279. The stock was the fourth biggest loser in A group. On the BSE, 58,000 shares were traded on the counter so far as against the average daily volumes of 80,000 shares in the past two weeks.

Reliance Communications slipped 2.9% to Rs 35.10. The stock was the fifth biggest loser in A group. On the BSE, 19.36 lakh shares were traded on the counter so far as against the average daily volumes of 37.03 lakh shares in the past two weeks.

Powered by Capital Market - Live News

Kotak Bank scales record high as board approves hike in foreign investment limit
Mar 08,2017

The announcement was made during market hours today, 8 March 2017.

Meanwhile, the S&P BSE Sensex was down 150.84 points or 0.52% at 28,848.72

A large bulk deal of 2.77 crore shares was executed on the scrip at Rs 827 per share in opening trade on BSE. Bulk deal boosted volume on the scrip. On the BSE, 2.77 crore shares were traded on the counter so far as against the average daily volumes of 2.15 lakh shares in the past one quarter.

The stock hit a high of Rs 839.75 in intraday trade so far, which is record high for the counter. The stock had hit a low of Rs 820.05 so far during the day. The stock had hit a 52-week low of Rs 631.50 on 15 March 2016.

The stock had outperformed the market over the past one month till 7 March 2017, advancing 6.51% compared with the Sensexs 1.97% rise. The scrip had also outperformed the market over the past one quarter, gaining 11.55% as against the Sensexs 10.53% rise.

The large-cap bank has equity capital of Rs 919.93 crore. Face value per share is Rs 5.

Kotak Mahindra Banks net profit rose 38.6% to Rs 879.76 crore on 11.02% growth in total income to Rs 5377.83 crore in Q3 December 2016 over Q3 December 2015.

Kotak Mahindra Bank is one of the leading private sector banks in India.

Powered by Capital Market - Live News

Volumes jump at Warren Tea counter
Mar 08,2017

Warren Tea clocked volume of 22.96 lakh shares by 12:55 IST on BSE, a 753.63-times surge over two-week average daily volume of 3,000 shares. The stock was unchanged at Rs 141.

James Warren Tea notched up volume of 22.78 lakh shares, a 744.09-fold surge over two-week average daily volume of 3,000 shares. The stock jumped 10.01% at Rs 156.

Kotak Mahindra Bank saw volume of 2.77 crore shares, a 197.19-fold surge over two-week average daily volume of 1.41 lakh shares. The stock rose 0.73% at Rs 823.25 after a large bulk deal of 2.77 crore shares was executed on the scrip at Rs 827 per share in opening trade on BSE.

Aarti Industries clocked volume of 4.2 lakh shares, a 137.81-fold surge over two-week average daily volume of 3,000 shares. The stock jumped 4.99% at Rs 782.30.

AIA Engineering saw volume of 96,000 shares, a 42.43-fold rise over two-week average daily volume of 2,000 shares. The stock rose 0.03% at Rs 1,479.

Powered by Capital Market - Live News

Jaiprakash Power gains after reports Brookfield plans to acquire three power plants
Mar 08,2017

Meanwhile, the S&P BSE Sensex was down 171.20 points or 0.58% at 28,830.17.

On the BSE, 9.82 lakh shares of Jaiprakash Power Ventures exchanged hands so far compared with average daily volume of 18.77 lakh shares in the past one quarter. The stock had hit a high of Rs 6.05 and a low of Rs 5.80 so far during the day. The stock had hit a 52-week high of Rs 6.96 on 26 July 2016. The stock had hit a record low of Rs 3.60 on 16 December 2016.

The stock had underperformed the market over the past one month till 7 March 2017, falling 4.64% compared with 2.34% gains in the Sensex. The scrip had, however, outperformed the market in past one quarter, gaining 40.24% as against Sensexs 10.53% gains.

The mid-cap company has equity capital of Rs 5996 crore. Face value per share is Rs 10.

Reports suggested that the discussions are in initial stages and there is no certainty that a transaction will take place. A deal, if it happens, could close at an equity value of Rs 4500-5000 crore, report added.

The transaction will mark Brookfields first investment in Indias power sector. Jaiprakash Power Ventures major lenders such as ICICI Bank, IDBI Bank and Punjab National Bank took control after the firm failed to repay loans on time.

On 20 February 2017, Jaiprakash Power Ventures allotted 305.8 crore shares to its 23 lenders as part of a debt restructuring scheme. Subsequent to the allotment of the shares, the lenders would collectively hold 51% of the post issue equity share capital and the outstanding loan amount of the company would stand reduced by Rs 3058 crore. The company as well as its subsidiaries shall cease to be subsidiaries of Jaiprakash Associates.

The Jaypee group has been trying to sell assets, including core ones, in the past two years after intense pressure from lenders. In July last year, the group sold its cement business to Aditya Birla Group firm UltraTech Cements for Rs 19500 crore. JPs power portfolio of 4,000 megawatts includes one hydro power plant and two thermal units.

Toronto-based Brookfield is the worlds second-biggest manager of alternative assets such as real estate and private equity.

Jaiprakash Power Ventures reported net loss of Rs 172.96 crore in Q3 December 2016 compared with net loss of Rs 115.81 crore in Q3 December 2015. Net sales fell 16.2% to Rs 693.10 crore in Q3 December 2016 over Q3 December 2015.

Jaiprakash Power Ventures is a power company and a part of Infrastructure conglomerate - Jaypee Group. The company plans, develops, implements and operates power projects in India.

Powered by Capital Market - Live News

Wockhardt drops as HPRA inspects Aurangabad facility
Mar 08,2017

The announcement was made after market hours yesterday, 7 March 2017.

Meanwhile, the S&P BSE Sensex was down 152.67 points, or 0.53%, to 28,846.89

On the BSE, 2.07 lakh shares were traded on the counter so far as against the average daily volumes of 2.21 lakh shares in the past one quarter. The stock had hit a high of Rs 736 and a low of Rs 711.10 so far during the day.

The stock had hit a 52-week high of Rs 1,129 on 21 July 2016 and a 52-week low of Rs 627 on 27 December 2016. The stock had outperformed the market over the past one month till 7 March 2017, advancing 3.15% compared with the Sensexs 1.97% rise. The scrip, however, underperformed the market over the past one quarter, gaining 7.48% as against the Sensexs 10.53% rise.

The mid-cap company has equity capital of Rs 55.27 crore. Face value per share is Rs 5.

Wockhardt said that the Health Products Regulatory Authority of Ireland (HPRA) has inspected its Shendra, Aurangabad facility and has recommended the renewal of certificate based on the general compliance with the principles and guidelines of Good Manufacturing Practice of Shendra manufacturing unit.

Wockhardt reported consolidated net loss of Rs 53.91 crore in Q3 December 2016, as compared to net profit of Rs 72.04 crore in Q3 December 2015. Net sales fell 7.3% to Rs 995.56 crore in Q3 December 2016 over Q3 December 2015.

Wockhardt is a research based and technology intensive global pharmaceutical and biotechnology company.

Powered by Capital Market - Live News